Penny Gilbert from Powell Gilbert LLP explains the position of biosimilars in the pharmaceutical industry. Biosimilars are essentially generic versions of biologics. Traditional generic compounds are  chemical reproductions of the patented compound which makes regulatory approval more straightforward. Biological compounds (proteins or antibodies which are produced from genes) are not identical with one another and…

Adam Mossoff (Professor of Law, George Mason University) states that much of the focus in the USA is around litigation, but patents are not simply tools for litigation, they are commercial assets. Litigation is more public than confidential private transactions and therefore has disproportionate focus. He remarked that the ‘sewing machine wars’ of the 1850s…

Marleen H J van den Hors (BarentsKrans in the Netherlands) dealt with the interesting question of enforcement of second medical use patents and suggested that regulatory changes might be required to facilitate enforcement.  She pointed out that there has been different interpretations of Swiss-style claims in the Netherlands and the UK leading to a different…

A panel of international judges gave their interesting perspectives on the tribunals on which they serve and the cases which they hear. Annabelle Bennett (Federal Court of Australia) discussing case management in Australia introducing reforms to streamline procedure and how this has been successful (in taking some power away from the lawyers). In particular, she…

Dimitrios T Drivas (White & Case) gave the speedy run down on the following points and cases, which some might find useful for following up on points of interest: Supreme Court The decision that in exceptional cases reasonable attorney’s fees may be paid to the prevailing party (an exception to the rule that each party…

The Unitary Patent and the UPC in Practice Paul England (Taylor Wessing) described the infringement position under the UPC Agreement and the UP Regulation (1257/2012). He explained that there was concern that the UP Regulation infringement provisions would be referable to the CJEU which was seen as undesirable and these were replaced with Article 5(3). This…